NIAID Site Search

Last Reviewed: September 25, 2024

This NIH Strategic Plan for Tickborne Disease Research proposes building on current trans-NIH efforts to better understand the complex interplay among host, tick, and pathogen factors that contribute to TBDs and the body’s defenses against them.

Last Reviewed: May 7, 2025

DMID - Peripheral Blood Mononuclear Cell (PBMC) and Associated Plasma Collection

Last Reviewed: March 12, 2025

Oye Nana Akuffo, M.B.A., of the Noguchi Memorial Institute for Medical Research, University of Ghana, Legon G11 sample application

Last Reviewed: March 31, 2025

Peter Rebeiro, Ph.D., of the Vanderbilt University Medical Center K01 sample application

Last Reviewed: March 31, 2025

Sample application from Emily Troemel, Ph.D., for NIH standard independent research project grant (R01).

Last Reviewed: October 11, 2024

To ensure a strong and diverse workforce and better understand workforce composition and participation in NIH programs, NIH regularly assesses the sex/gender, race, ethnicity,and disability status of its supported researchers.

Published: February 1, 2023

Directions to the Vaccine Research Center located on the National Institutes of Health (NIH) campus in Building 40.

Last Reviewed: May 12, 2008

MALDI Biotyper (MBT) is a technology that identifies microorganisms using matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry to measure a unique peptide mass fingerprint. MBT measures highly abundant proteins that are found in all microorganisms and matches the pattern with a spectral library to determine the microorganism (in some cases down to the species

Last Reviewed: November 17, 2017

Concepts represent early planning stages for program announcements, requests for applications, notices of special interest, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to Opportunities & Announcements. Note: Council approval does not guarantee that a concept will become an initiative. Table of

Last Reviewed: September 18, 2023

NIAID is soliciting contract proposals from offerors capable of providing a broad range of services to investigate vaccine formulations with HIV immunogens and adjuvants.

Published: March 1, 2023

Last Reviewed: August 6, 2024

Liu Application

Last Reviewed: November 5, 2024

Severe COVID-19 may cause long-lasting alterations to the innate immune system, the first line of defense against pathogens, according to a small study funded by the National Institute of Allergy and Infectious Diseases.

Published: August 18, 2023

Misrak Gezmu, Ph.D., is a Mathematical Statistician in the Biostatistics Research Branch at the National Institute of Allergy and Infectious Diseases.

Last Reviewed: December 1, 2022

Last Reviewed: August 6, 2024

Last Reviewed: August 6, 2024

The goal of this clinical trial is to compare antifungal therapy duration in pediatric uncomplicated candidemia.

Concepts represent early planning stages for program announcements, requests for applications, notices of special interest, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to Opportunities & Announcements. Note: Council approval does not guarantee that a concept will become an initiative. Table of

Last Reviewed: August 5, 2024

Although the spread of HIV has slowed down thanks to risk-reduction measures, prevention efforts, and oral antiretroviral preexposure prophylaxis (PrEP), there are more than 1.5 million new cases of the human immunodeficiency virus (HIV) each year worldwide. The Antibody Mediated Prevention trials included two clinical trial cohorts, to test the ability of the monoclonal antibody VRC01 to prevent

Published: March 18, 2021

Sample application from David Al-Adra MD, Ph.D., for NIH standard independent research project grant (K08).

Last Reviewed: September 13, 2024

The purpose of this study is to see if vorinostat is safe for people with moderate-to-severe CD and to see if it is safe for people with moderate-to-sever CD to receive maintenance therapy using Ustekinumab after successful treatment of Vorinostat.

Information about how to talk to your doctor about primary immune deficiency diseases from NIAID.

Last Reviewed: December 5, 2015

Dr. Fauci, who since 1984 has directed the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, reflects on his career responding to infectious disease threats.

Published: November 28, 2022

An experimental therapeutic cancer vaccine induced two distinct and desirable immune system responses that led to significant tumor regression in mice, report investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The researchers found that intravenous (IV) administration of the vaccine boosted the number of cytotoxic T

Published: November 10, 2022